Clinical Trial

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2024-11-19; most recent amendment 2026-05-13.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-01-27
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-12-13
Trial Details
NCT Number NCT06696443
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Diabetic Peripheral Neuropathic Pain
Enrollment 455 participants
Start Date 2024-12-18
Primary Completion 2027-01-25 (estimated)
Study Completion 2027-01-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-18